Using the Brief Assessment of Cognition in Schizophrenia (<scp>BACS</scp>) to assess cognitive impairment in older patients with schizophrenia and bipolar disorder

Cholet, Jennyfer; Sauvaget, Anne; Vanelle, Jean-Marie; Hommet, Caroline; Mondon, Karl; Mamet, Jean-Philippe; Camus, Vincent

doi:10.1111/bdi.12171

Cited by 24 publications

(20 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found 53 articles on OABD in the last 6 years . Of those, 50 (94%) papers examined clinical samples ranging from 10 to 315 subjects (total of 3302 subjects, mean ± standard deviation (SD) 62.3 ± 51.5 subjects/paper, median 53 subjects/paper).…”

Section: Resultsmentioning

confidence: 99%

“…All studies ( n = 53) reported age and gender. Levels of education were the next most often reported ( n = 34 studies, 64%), followed by ethnicity ( n = 23, 43%) and marital status ( n = 17, 32%) …”

Section: Resultsmentioning

confidence: 99%

“…For manic symptoms, the Young Mania Rating Scale (YMRS) was mostly widely used ( n = 29, 55%) . Several scales for depressive symptoms were used, such as the Hamilton Depression Rating Scale ( n = 21, 40%), and the Montgomery‐Asberg Depression Rating Scale (MADRS) ( n = 8, 15%), with only one study using a mood chart . Only three studies assessed for a history of psychotic symptoms (6%), and only one study reported the use of a psychotic symptom severity measure (2%) (Positive and Negative Syndrome Scale, and Scale for the Assessment of Negative Symptoms) …”

Section: Resultsmentioning

confidence: 99%

“…Current use of medication was often reported for anticonvulsants ( n = 14, 26%), antipsychotics ( n = 23, 43%), antidepressants ( n = 23, 43%), benzodiazepines ( n = 13, 25%) and lithium ( n = 23, 43%) . Some studies gave information about the number of years of lithium exposure ( n = 6, 11%) and exposure to other drugs ( n = 3). Only two studies reported relative dose of current antipsychotic exposure, using chlorpromazine equivalences, and only one study used an instrument developed to assess past pharmacological exposure .…”

Section: Resultsmentioning

confidence: 99%

“…Sixty‐two per cent of studies ( n = 33) included at least one measure of cognitive performance. The median and mean (standard deviation) number of cognitive tests used by each study were 1 and 3.3 (5.0), respectively.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Measurement tools for assessment of older age bipolar disorder: A systematic review of the recent global literature

et al. 2017

View full text Add to dashboard Cite

Assessment tools used in the recent OABD literature may help to identify both a minimum and a comprehensive dataset that should be evaluated in OABD. Our review also highlights gaps where key clinical outcomes have not been routinely assessed. Biomarker and neuroimaging assessment could be further developed and standardized. Clinical data could be combined with neuroimaging, genetic, and other biomarkers in large-scale coordinated data collection to further improve our understanding of OABD phenomenology and biology, thereby contributing to research that advances care.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Measurement tools for assessment of older age bipolar disorder: A systematic review of the recent global literature

et al. 2017

View full text Add to dashboard Cite

show abstract

Long-term consequences of COVID-19 on cognitive functioning up to 6 months after discharge: role of depression and impact on quality of life

Poletti

Palladini

Mazza

et al. 2021

Eur Arch Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Neurologic and psychiatric symptoms have been reported in the months following the infection with COVID-19. A low-grade inflammation has been associated both with depression and cognitive symptoms, suggesting a link between these disorders. The aim of the study is to investigate cognitive functioning 6 months following hospital discharge for COVID-19, the impact of depression, and the consequences on quality of life. Ninety-two COVID-19 survivors evaluated at 1-month follow-up, 122 evaluated at 3 months and 98 evaluated at 6 months performed neuropsychological and psychiatric evaluations and were compared with a healthy comparison group (HC) of 165 subjects and 165 patients with major depression (MDD). Cognitive performances were adjusted for age, sex, and education. Seventy-nine percent of COVID-19 survivors at 1 month and 75% at 3- and 6-month follow-up showed cognitive impairment in at least one cognitive function. No significant difference in cognitive performances was observed between 1-, 3-, and 6-months follow-up. COVID-19 patients performed worse than HC but better than MDD in psychomotor coordination and speed of information processing. No difference between COVID-19 survivors and MDD was observed for verbal fluency, and executive functions, which were lower than in HC. Finally, COVID-19 survivors performed the same as HC in working memory and verbal memory. The factor that most affected cognitive performance was depressive psychopathology which, in turn, interact with cognitive functions in determining quality of life. Our results confirm that COVID-19 sequelae include signs of cognitive impairment which persist up to 6 months after hospital discharge and affect quality of life. Supplementary Information The online version contains supplementary material available at 10.1007/s00406-021-01346-9.

show abstract

Rapid screening for cognitive deficits in attention deficit and hyperactivity disorders with the screen for cognitive impairment in psychiatry

Tourjman

Potvin

Corbalán

et al. 2018

ADHD Atten Def Hyp Disord

View full text Add to dashboard Cite

Cognitive impairments constitute a core feature of attention deficit and hyperactivity disorders (ADHD), but are infrequently assessed in the clinical setting. We have previously demonstrated the ability of an objective cognitive battery, the Screen for Cognitive Impairment in Psychiatry (SCIP), to differentiate adult ADHD patients from healthy controls in five cognitive domains. Here, we further characterize these subtle cognitive deficits by conducting additional univariate analyses on our ADHD dataset to assess the contributions of various demographic characteristics on SCIP performance and to determine correlations between SCIP scores and scores on other measures evaluating illness severity, perceived cognitive deficits, and overall functioning. Age and years of education were moderately associated with performance on the SCIP and/or its subscales in our ADHD cohort. The SCIP global index score was moderately correlated with clinician-rated measures of illness severity and weakly associated with clinician-rated overall functional status. Intriguingly, overall SCIP performance was only weakly associated with patient self-reported measures of cognitive functioning. Of practical importance, small-to-moderate associations were consistently observed between performances on two subscales of the SCIP and the other measures evaluating illness severity, overall functioning, and patient self-reported cognitive functioning (the working memory and visuomotor tracking subscales). Thus, these data demonstrate that the SCIP, particularly the working memory and visuomotor tracking subscales, is sensitive enough to detect cognitive deficits in adult patients with ADHD, and that these deficits are correlated with functional impairments. Furthermore, these data highlight the importance of integrating both objective and subjective evaluations of cognition in adult ADHD.

show abstract

Using the Brief Assessment of Cognition in Schizophrenia (BACS) to assess cognitive impairment in older patients with schizophrenia and bipolar disorder

Abstract: The BACS appears to be a feasible and informative cognitive assessment tool for elderly patients with bipolar disorder. We believe that these preliminary results merit further investigation.

Cited by 24 publications

References 67 publications

Measurement tools for assessment of older age bipolar disorder: A systematic review of the recent global literature

Measurement tools for assessment of older age bipolar disorder: A systematic review of the recent global literature

Long-term consequences of COVID-19 on cognitive functioning up to 6 months after discharge: role of depression and impact on quality of life

Rapid screening for cognitive deficits in attention deficit and hyperactivity disorders with the screen for cognitive impairment in psychiatry

Contact Info

Product

Resources

About